Baseline demographics and disease characteristics
| . | CML-CP (n = 95) . | CML-AP (n = 27) . |
|---|---|---|
| Median age, y (range) | 59 (29-82) | 58 (31-76) |
| Male, % | 40 | 44 |
| Previous history of imatinib therapy | ||
| Median duration of previous imatinib, mo (range) | 14 (0.3-64) | 9 (0.1-68) |
| Previous greatest dose of imatinib, n (%) | ||
| < 400 mg/d | 0 | 1 (4) |
| 400 to < 600 mg/d | 63 (66) | 17 (63) |
| 600 to < 800 mg/d | 16 (17) | 7 (26) |
| 800 mg/d or greater | 15 (16) | 2 (7) |
| Missing | 1 (1) | 0 |
| Duration of CML | ||
| Median time since first diagnosis of CML, mo (range) | 40 (5-266) | 57 (2-161) |
| Best response to imatinib, n (%) | ||
| CHR (no CyR) | 35 (37) | 2 (7) |
| Any CyR | 47 (49) | 3 (11) |
| . | CML-CP (n = 95) . | CML-AP (n = 27) . |
|---|---|---|
| Median age, y (range) | 59 (29-82) | 58 (31-76) |
| Male, % | 40 | 44 |
| Previous history of imatinib therapy | ||
| Median duration of previous imatinib, mo (range) | 14 (0.3-64) | 9 (0.1-68) |
| Previous greatest dose of imatinib, n (%) | ||
| < 400 mg/d | 0 | 1 (4) |
| 400 to < 600 mg/d | 63 (66) | 17 (63) |
| 600 to < 800 mg/d | 16 (17) | 7 (26) |
| 800 mg/d or greater | 15 (16) | 2 (7) |
| Missing | 1 (1) | 0 |
| Duration of CML | ||
| Median time since first diagnosis of CML, mo (range) | 40 (5-266) | 57 (2-161) |
| Best response to imatinib, n (%) | ||
| CHR (no CyR) | 35 (37) | 2 (7) |
| Any CyR | 47 (49) | 3 (11) |
AP indicates accelerated phase; CHR, complete hematologic response; CML, chronic myeloid leukemia; CP, chronic phase; and CyR, cytogenetic response.